Myelodysplastic syndromes (MDS) are a challenging group of diseases for clinicians and researchers, as both disease course and pathobiology are highly heterogeneous. In (suspected) MDS patients, multi-parameter flow cytometry can aid in establishing diagnosis, risk stratification and choice of therapy. This review addresses the developments and future directions of multi-parameter flow cytometry scores in MDS. Additionally, we propose an integrated diagnostic algorithm for suspected MDS.
Introduction
The knowledge on and management of myelodysplastic syndromes (MDS) have taken a flight over the past decades; major parts of the pathobiology have been elucidated, several additional diagnostic and prognostic tools implemented and novel therapies discovered [1] [2] [3] [4] [5] [6] . Nevertheless, MDS are still a challenging group of diseases, mostly due to their extensive heterogeneity and often non-clear-cut diagnosis [7, 8] . Hence, several questions are raised by clinicians treating MDS-patients: How certain is this MDS-diagnosis? Is this patient at risk for leukemic transformation or bone marrow failure? What is the chance this patient will respond to a certain therapy? This review is based on the lecture from AA van de Loosdrecht at the European Bone Marrow Working group 2017 on multi-parameter flow cytometry (MFC) and gives an overview of how MFC can support clinicians in the work-up of (suspected) MDS patients. Additionally, we address improved implementation of MFC in routine practice and future perspectives.
MFC in MDS
Multi-parameter flow cytometry is one of the most extensively used techniques in diagnostic laboratory medicine in hematology, for it enables the evaluation of hematopoietic cells on a single cell level. by an altered antigen expression, frequency of cell subsets and scatter properties. Currently, many aberrancies of the progenitor cells, the myelomonocytic lineage and the erythroid lineage are well described. Altered immunophenotypic profiles have been shown useful in diagnosis, risk stratification and therapy guidance of MDS-patients. The International Working Group for FC in MDS (IMDSFlow) of the European Leukemia Net (ELNet) published guidelines for MFC in MDS [7, 9, 10] . Table 1 summarizes the flow cytometric characteristics per cell compartment that are recommended for evaluation by IMDSFlow.
Flow Cytometric Aberrancies per Cell Subset
The Progenitor Cell Compartment Quantifying blasts is of importance in MDS, as blast percentage by morphology discriminates MDS from acute myeloid leukemia (AML) [6] . Moreover, morphologic blast counts subdivide MDS in prognostic relevant sub categories according to World Health Organization classification as well as according to the revised International Prognostic Scoring System (IPSS-R) [5, 6] . MFC enables quantification of immature cells. However, multiple studies have shown that although [14] . For instance, myeloid progenitors can express lymphoid lineage-specific markers (Fig. 1) , have altered granulation reflected by the side scatter and have increased, decreased or aberrantly distributed marker expression. What is more, also B-cell progenitors can be quantitatively affected in MDS; absence or decrease in progenitor-B-cells is a frequently observed feature [15, 16] . However, this is not a MDS-specific feature and is commonly seen in other diseases and elderly patients.
The Maturing Myelomonocytic Lineage
Neutrophils in MDS are often decreased in frequency and hampered in function. Flow cytometry can detect aberrancies in neutrophils. Classical aberrancies in MDS are a decreased SSC, reflecting the morphologic paradigm of hypogranulation, and altered maturation patterns (Fig. 1) .
Monocytic dysplasia is difficult to assess by morphology, for monocyte frequency is low. Flow cytometry, however, is eminently useful in studying less frequent populations and hence, in monocytic evaluation. A frequently observed aberrancy on monocytes is an expression of CD56 (Fig. 1) . However, the activation and regeneration of bone marrow can also induce expression of CD56. Having knowledge on the clinical context of patients is therefore of importance. The optimal cut-off for the percentage of CD56 is yet to be determined. In case of (borderline) monocytosis in bone marrow or peripheral blood, chronic myelomonocytic leukemia (CMML) or CMML-like MDS should be considered. The evaluation of peripheral blood monocyte repartition by MFC is highly recommended in case of (borderline) monocytosis. Monocytes can be divided into 3 subtypes: classical CD14 positive/CD16 negative, intermediate CD14 positive/CD16 positive and nonclassical CD14low/CD16 positive. Monocytes in CMML are preferentially classical monocytes. The latter can be used as a diagnostic tool. Selimoglu-Buet et al. [17] showed that using a cut-off of > 94% classical monocytes, discriminates CMML from reactive monocytosis with a specificity of 95.1% and a sensitivity of 91.9% [17] [18] [19] [20] .
The Erythroid Lineage
Over 80 percent of MDS-patients have anemia at the time of diagnosis as a result of disturbed erythroid maturation. The first markers used to assess aberrant erythroid phenotype were CD235a and CD71 expression [21] . Currently, the most used and validated parameters are expression and distribution of CD36 and CD71. Also, relevant to address aberrant erythroid phenotype are CD34, CD117 and CD105 ( Fig. 1) [10]. Notably, when studying the erythroid lineage, the type of lysing procedure used during sample processing for MFC, or no lysing, is of importance, as some stringent lysing methods negatively impact the frequency of erythroid precursor subsets [10, 22] .
Additional Cell-Subsets of Interest
Megakaryocytic dysplasia is one of the most MDSspecific findings by morphology. Megakaryocytes, however, proved difficult to analyze by MFC due to frequency, size and cellular complexity. Possibly, platelet abnormalities may reflect dysplasia of megakaryocytes and can therefore be used as a substitute [21] . Sandes et al. [23] compared peripheral blood platelets in MDS (n = 44) with healthy controls thereby demon- strating differences in scatter, expression of CD34, CD36, CD42a and CD61. These findings have to be extensively validated due to confounders such as activation and inflammation before implementation in routine practice.
Several other hematopoietic cell subsets, involved in the dysplastic clone and/or in the immunopathogenesis of MDS, have been described, including aberrancies in mast cells, changes of frequency in plasmacytoid dendritic cells, myeloid dendritic cells (mDC1 and mDC2), myeloid-derived suppressor cells (MDSC) and T cell subsets [24, 25] . Increased frequencies of MDSCs and T-regulatory cells are thought to reflect an immunosuppressive environment in high risk MDS [2, 26] . The immunophenotype of MDSCs in humans, however, is not yet fully agreed upon [27] .
Considerations and Pitfalls
Technical considerations and pitfalls are described in detail by IMDSFlow and others [9, 28] . In short, to conduct a reliable MFC experiment, several aspects have to be taken into consideration, including sample handling, instrument settings and interpretation of results. First, the ELNet guidelines favour collecting bone marrow in tubes with heparin anticoagulant, as EDTA is known to influence marker expression such as CD11b. However, more important than the preference for heparin is standardized processing including anticoagulant and knowledge of the possible drawbacks of for instance EDTA. Second, time to processing of bone marrow is important (preferentially < 24 h after aspiration) as an increase in SSC on neutrophils and a decrease in numbers of CD14 positive monocytes has been observed in older samples. Subsequently, lysing procedures may influence marker expression and population size, especially with respect to the erythroid lineage as discussed above. Hereto, within a single center, standard processing including a uniform lysing procedure, or even refraining from a lysing procedure when analyzing the erythroid lineage, is essential.
Flow cytometry panels should contain optimal marker combinations to distinguish populations, evaluate maturation patterns and assess aberrant expression. Additionally, constructing a panel with minimal spectral overlap and proper compensation, measured on a flow cytometer with optimized instrument settings is essential [9, 28] . The Euroflow consortium compiled an MFCpanel for MDS/AML [29] . It contains most of the advised markers and combinations from IMDSFlow guidelines [30] . Several groups designed alternative MFC-panels for MDS (online suppl. Analysis of MFC data has to be performed by trained professionals with extensive knowledge on immunophenotypic profiles of normal bone marrow and other hematopoietic diseases. Examples of normal bone marrow flow cytometry can be found at the bone marrow MFC Atlas at the ELNet website [31] . Several findings can be misleading for less experienced staff. Examples of pitfalls are distinguishing low expression of CD33 due to a regularly occurring splicing variant (polymorphism) from aberrant low expression in MDS and distinguishing aberrant loss of marker expression from apoptosis-induced changes. In conclusion, optimal MFC analysis includes uniform sample handling, standardized instrument settings and knowledge on normal and pathological hematopoiesis.
Clinical Utility of MFC
Multi-parameter flow cytometry can be clinically applied for diagnosis, risk stratification and therapy monitoring. For these applications, several so-called MFC scores have been developed. MFC scores are generally based on the same concept: flow cytometric aberrancies encountered in MDS are scored and combined to establish either diagnosis or a risk profile. Typically, a high number of aberrancies represents a higher diagnostic accuracy and a higher risk for leukemic transformation. Substantial differences in MFC-scores are encountered in combination of markers, the amount of parameters (from single to several) and the weight assigned to each parameter [30, 32, 33] .
MFC-Scores for Diagnosis
Myelodysplastic syndromes can be difficult to distinguish from other (non)clonal causes of cytopenia. Dysplasia according to cytomorphology and histopathology combined with cytogenetic aberrancies is considered the gold standard [6] . However, 50% of MDS-cases have normal cytogenetics and assessment of dysplasia is not always clear-cut and known to be subjected to inter-user variability [34] . Moreover, dysplasia can be caused by several other factors such as intoxications and medication. In 2012, the ELNet added MFC-scores as a recommended tool in the diagnostic work-up of MDS [35] . These guidelines were updated recently and the additive value of MFC is continuously acknowledged [7] . The latest edition of the World Health Organization Classification of Tu- mours of Haematopoietic and Lymphoid Tissues contains a similar recommendation [36] .
Over a dozen diagnostic-MFC scores have been developed since Stetler-Stevenson et al. [21] published the first score in 2001. Here, we discuss the Ogata-score, the RED-score, the erythroid parameters of the IMDSflow and the Integrated Flow score (iFCs) including the Flow Cytometric Scoring System (FCSS) of Wells et al. [30, 33] . The Ogata score is a 4-parameter score consisting of the SSC on neutrophils related to SSC of lymphocytes, percentage of progenitor B-cells within the CD34+ compartment, the percentage of CD34+ myeloid progenitors of nucleated cells and the CD45 expression on CD34+ progenitors related to that of lymphocytes. This score displays a sensitivity of 72% and a specificity of 93% in low risk MDS-patients and cytopenic controls respectively [32, 37] . The Ogata score is practical and relatively simple; however, sensitivity has proven to be insufficient in low risk MDS. Over the past years, 2 studies to evaluate the erythroid lineage have been published by Mathis et al. [38] and IMDSflow. They first developed the REDscore that includes the variation in fluorescence intensity of CD36 and CD71 on the erythroid lineage and haemoglobin levels [38] . Combining the RED-score with the Ogata score shows a sensitivity of 88 percent and a specificity of 89% [38] . The second study concerns the erythroid parameters recommended by IMDSFlow: CD36 and CD71 distribution and CD36 expression on the erythroid lineage and the percentage CD117+ erythroid precursors. If combined with the Ogata score, it has a sensitivity of 86% and a specificity of 95%. Hence, combining erythroid parameters with the Ogata score increases sensitivity. Integrating the Ogata-score, Wells' FCSS and the IMDSFlow erythroid markers, into the socalled iFCs showed 80% sensitivity and 95% specificity. The FCSS evaluates the (im)mature myelomonocytic lineage and has 75% sensitivity and 100% specificity when used independently [10, 33, 39] . A multicenter study within the IMDSFlow WG is launched to evaluate which parameters are most powerful for separating MDS from other causes of cytopenia.
Diagnostic MFC-scores are thought to have the highest additive value in suspected MDS with normal cytogenetics and inconclusive bone marrow morphology [40, 41] . In these patients, MFC may circumvent the need for a second diagnostic bone marrow aspirate and reduce the risk of false positive or false negative diagnosis. Additionally, MFC-scores might aid in managing several recently defined MDS-related syndromes, such as idiopathic dysplasia of undetermined significance, clonal hematopoiesis of indeterminate potential and clonal cytopenia of undetermined significance [42] [43] [44] .
MFC Scores in Risk Stratification
Myelodysplastic syndromes are characterized by a heterogeneous disease course, ranging from a stable, smouldering cytopenia without need for treatment to rapid bone marrow failure or leukemic transformation. The IPSS-R is the most refined tool for risk stratification [5] . However, in the low risk category patients, AML evolution is observed up to 25% in 10 years and patients categorized as high risks do not always develop AML, indicating the need for some refinement. As mentioned above, most MFC scores have both diagnostic and prognostic values. Several have proven to be of prognostic value within IP-SS-R risk groups [30, 45] . For example, Della Porta et al. [45] have shown that the Ogata-score has prognostic value in low-risk MDS within IPSS-R subcategories. Moreover, we and others have shown that the number of aberrancies in the FCSS is associated with transfusion dependency, earlier progression of disease, leukemia-free survival and overall survival. A 3-parameter score developed solely for prognosis by Alhan et al. [46] has prognostic value beyond the IPSS-R low risk category. They combined CD13 expression on monocytes with sideward light scatter and CD117 expression of myeloid progenitor cells [46] . Other parameters that have negative prognostic value in the lower risk categories are a low progenitor Bcell abundance combined with an increase in regulatory T-cells. Moreover, Chen et al. [47] showed that an increased CD200 expression on CD33+ bone marrow cells is a poor-prognostic parameter independent of the IPSS.
Choice of Treatment and Therapy Monitoring
Few studies have looked into the potential of MFC as a tool for therapy selection and guidance. The first MFC-score with therapy guiding potential was the FCSS, namely, in predicting outcome after stem cell transplantation [30] . Westers et al. [48] showed that having aberrant progenitors negatively correlates with response to growth factor treatment. The same relation for response to azacitidine in intermediate-2 and high-risk MDS patients was shown [49] . Another interesting implementation for MFC is therapy monitoring. Persistence or clearance of FC aberrancies may reflect response to therapy. A recent study showed that MDS with isolated del(5q) has a typical immunophenotypic profile that can be used to evaluate treatment response and support treatment decisions [50] .
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Future Perspectives

Implementation in Routine Practice
Multi-parameter flow cytometry is a valuable tool in the complicated diagnostic process of MDS and has additive value in risk stratification and therapy guidance. However, its clinical value is not fully reflected by the degree of implementation in routine practice. One of the causes may be the amount of parameters of interest and the variety of MFC scores. IMDSFlow has published clear guidelines on which markers are the most relevant [9] . However, this recommended marker panel includes a vast amount of markers resulting in a complex and costly analysis. Ideally, minimal MFC panels for diagnosis, prognosis and treatment guidance should be compiled by selecting the most powerful markers from large data sets.
Another improvement to increase diagnostic implementation could be a clear flowchart for the diagnostic work-up of cytopenic patients suspected for having MDS including MFC. In Figure 2 , we propose a first draft (Fig. 2) . This flowchart shows how clinicians can implement diagnostic MFC scores. Moreover, it demonstrates that MFC will have the most impact in cytopenic cases without specific MDS morphological dysplasia and cytogenetic aberrancies. Yet, the accuracy of this diagnostic flowchart will depend on the sensitivity and specificity of the MFC score used. We propose the use of a validated score, such as the iFCs or the Ogata score combined with IMDSFlow erythroid parameters [10, 33] . Validation of the proposed diagnostic flowchart is required before implementation.
Regarding risk-stratification, the development of a prognostic scoring system combining clinical parameters and morphology with results from flow cytometry and NGS, similar as was recently published for AML, is of interest [51] .
Another cause for the limited implementation of MDS-MFC in routine practice is, presumably, the challenging and time-consuming analysis. Currently, most flow cytometry data is analyzed manually: 2D-plots are inspected visually and cells are assigned to subpopulations based on current knowledge. Over the past decade computational knowledge and power has increased and several automated visualization, clustering and analysis tools have been developed [52, 53] . Implementation could decrease the time and expertise needed for analysis and more importantly the subjectivity that is inherent to manual analysis. Most visualization tools apply dimensionality reduction to comprehensively visualize multi-dimensional data in a two-dimensional manner. Jafari et al. [54] applied a visualization method on MFC data of MDS patients and healthy patients called radar-plots. They showed that this method is able to group cells in accordance with manual gating strategies. Moreover, the radar plots show clear differences between MDS bone marrow and healthy bone marrow and hence, may provide a faster and less subjective way of analyzing. In other hematopoietic malignancies, several automated analysis tools for population identification, diagnostics and detection of minimal residual disease (MRD) are being developed that may provide diagnostic and/or prognostic information with high accuracy. For example, the detection of chronic lymphocytic leukemia, multiple myeloma cells and MRD in multiple myeloma can be automated, as is the case for MRD analysis and subgrouping in AML [55] [56] [57] [58] .
Another interesting application of automated data analysis is risk stratification. The latest challenge of "Flow-CAP," an initiative to improve computational flow cytometry data analysis, showed several algorithms that accurately predicted the time to progression from HIV to AIDS using flow cytometric data [59] . In short, there is a broad range of possibilities for automated analysis, although implementation in MDS is currently limited. Further improvements to MFC-scores could be achieved by the application of recent technical developments that might give us more insight in specific immunophenotypic profiles of MDS. For example, the increasing number of parameters per cell that can be measured simultaneously using either flow cytometry or mass cytometry can increase the chance of discovering novel MDS-specific markers and cell subsets.
Conclusion
Multi-parameter flow cytometry supports clinicians by answering challenging questions dealing with the management of MDS-patients, as it is useful in diagnosis, risk stratification and therapy guidance. Further research is required to compile optimal and simple panels that can be easily implemented in routine laboratory medicine. Additionally, embracing novel techniques such as automated analysis and high-dimensional single-cell analysis will, potentially increase the clinical impact of MFC.
